Birmingham Biotech

About Us

Birmingham Biotech LTD and Birmingham Biomat LTD are building a world-class biomaterial and mucosal protection platform through close collaboration with the University of Birmingham. Led by internationally recognised scientists such as Professor Liam Grover (FMedSci) and Dr. Richard Moakes, we unite academic excellence with commercial execution to deliver scientifically led, drug-free healthcare innovations designed for global impact.

Our Focus

- Birmingham Biomat – the dedicated R&D and platform innovation hub, advancing novel biomaterial-based healthcare technologies with preventive and therapeutic potential.
- Birmingham Biotech – responsible for regulatory approval, GMP manufacturing, and worldwide market deployment, ensuring innovations achieve safe and scalable access worldwide.

Our Portfolio

- NoriZite® – internationally recognised nasal sprays providing everyday, drug-free respiratory protection through barrier technology.
- Rinofast® – paediatric nasal care solutions designed for gentle, effective daily protection in children and infants.
- NoriZite® Eye Spray – a barrier spray offering long-lasting hydration and comfort for individuals experiencing dry eye or ocular irritation.
- RiNOZiTE® – intimate health gel certified under European medical device standards, delivering safe hydration, comfort, and protective care.
- Pipeline innovations – including wound-healing membranes, anti-fibrosis sprays, and other biomaterial-based preventive healthcare solutions.

Our Vision

By collaborating with world-leading academics and institutions, we are setting a global benchmark for drug-free prevention and care. Our platform-driven approach strengthens healthcare resilience, supports healthy ageing, and delivers sustainable innovations that improve quality of life for millions worldwide.